



New Insights of Management of Hepatocellular Carcinoma

Guest Editors:

Prof. Dr. Oliver Waidmann

Centrum für Hämatologie und
Onkologie Bethanien, Im Prüfling
17-19, 60389 Frankfurt/Main,
Germany

Dr. Fabian Finkelmeier

Department of Gastroenterology,
Hepatology and Endocrinology,
University Hospital Frankfurt,
Frankfurt/ Main, Germany

Dr. Vera Himmelsbach

Department of Gastroenterology,
Hepatology and Endocrinology,
University Hospital Frankfurt,
Frankfurt/ Main, Germany

Deadline for manuscript
submissions:

closed (31 August 2023)

Message from the Guest Editors

Dear Colleagues,

After a long dry spell, HCC treatment paradigms have rapidly changed in recent years. Introduction of immunotherapy and immunotherapy-based treatment concepts in clinical routine became a door opener for new treatment concepts in this hard-to-treat disease. Immunotherapeutic-based combinations regimens in particular show highly objective responses rates, offering the use of these concepts in advanced disease for downstaging or rendering metastatic disease to potentially curative treatment. This Special Issue of Cancers invites manuscripts focusing on treatment concepts and biomarkers which might help to identify special patient populations, treatment concepts, or biomarkers who show high responses and might guide the choice of treatment.

Prof. Dr. Oliver Waidmann

Dr. Fabian Finkelmeier

Dr. Vera Himmelsbach

Guest Editors





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)